Welcome to LookChem.com Sign In|Join Free
  • or
Inositol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

87-89-8

Post Buying Request

87-89-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

87-89-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 87-89-8 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 8 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 87-89:
(4*8)+(3*7)+(2*8)+(1*9)=78
78 % 10 = 8
So 87-89-8 is a valid CAS Registry Number.
InChI:InChI=1/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4+,5-,6-

87-89-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (A13586)  myo-Inositol, 98+%   

  • 87-89-8

  • 100g

  • 239.0CNY

  • Detail
  • Alfa Aesar

  • (A13586)  myo-Inositol, 98+%   

  • 87-89-8

  • 500g

  • 955.0CNY

  • Detail
  • Alfa Aesar

  • (A13586)  myo-Inositol, 98+%   

  • 87-89-8

  • 2500g

  • 4046.0CNY

  • Detail
  • Sigma-Aldrich

  • (57570)  myo-Inositol  for microbiology, ≥99.0%

  • 87-89-8

  • 57570-25G

  • 379.08CNY

  • Detail
  • Sigma-Aldrich

  • (57570)  myo-Inositol  for microbiology, ≥99.0%

  • 87-89-8

  • 57570-100G

  • 960.57CNY

  • Detail
  • Sigma-Aldrich

  • (57570)  myo-Inositol  for microbiology, ≥99.0%

  • 87-89-8

  • 57570-500G

  • 3,704.22CNY

  • Detail
  • Sigma-Aldrich

  • (PHR1351)  Inositol  pharmaceutical secondary standand; traceable to USP and PhEur

  • 87-89-8

  • PHR1351-1G

  • 732.19CNY

  • Detail
  • Sigma-Aldrich

  • (Y0000485)  myo-Inositol  European Pharmacopoeia (EP) Reference Standard

  • 87-89-8

  • Y0000485

  • 1,880.19CNY

  • Detail
  • USP

  • (1340960)  Inositol  United States Pharmacopeia (USP) Reference Standard

  • 87-89-8

  • 1340960-500MG

  • 4,662.45CNY

  • Detail
  • Sigma

  • (I5125)  myo-Inositol  ≥99%

  • 87-89-8

  • I5125-10MG

  • 242.19CNY

  • Detail
  • Sigma

  • (I5125)  myo-Inositol  ≥99%

  • 87-89-8

  • I5125-50G

  • 458.64CNY

  • Detail
  • Sigma

  • (I5125)  myo-Inositol  ≥99%

  • 87-89-8

  • I5125-100G

  • 816.66CNY

  • Detail

87-89-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name myo-inositol

1.2 Other means of identification

Product number -
Other names bios I

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:87-89-8 SDS

87-89-8Synthetic route

(+/-)-1,2:4,5-di-O-isopropylidene-myo-inositol
51548-88-0, 96039-15-5, 98974-89-1, 128110-25-8

(+/-)-1,2:4,5-di-O-isopropylidene-myo-inositol

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
palladium dihydroxide In methanol for 88h; Heating;97%
2,4,6-tri-O-benzyl-1,3,5-O-orthoformate-D-myo-inositol

2,4,6-tri-O-benzyl-1,3,5-O-orthoformate-D-myo-inositol

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
palladium dihydroxide In methanol for 72h; Heating;96%
With Pd(OH)2/C In methanol for 72h; Reflux;
(±)-2,3:5,6-di-O-isopropylidene-1,4-di-O-benzyl-myo-inositol

(±)-2,3:5,6-di-O-isopropylidene-1,4-di-O-benzyl-myo-inositol

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
palladium dihydroxide In methanol for 22h; Heating;95%
1D-1-O-Acetyl-myo-inositol

1D-1-O-Acetyl-myo-inositol

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With sodium methylate In methanol at 70℃; for 3h; Deacetylation;94%
2-O-tert-butyldimethyl-myo-inositol 4,6-carbonate 1,3,5-orthoformate

2-O-tert-butyldimethyl-myo-inositol 4,6-carbonate 1,3,5-orthoformate

A

D-myo-inositol
87-89-8

D-myo-inositol

B

myo-inositol 4,6-carbonate

myo-inositol 4,6-carbonate

Conditions
ConditionsYield
With water; trifluoroacetic acid at 65 - 70℃;A n/a
B 83%
2-O-(tert-butyldimethylsilyl)-4,6-O-methylene-myo-inositol 1,3,5-orthoformate

2-O-(tert-butyldimethylsilyl)-4,6-O-methylene-myo-inositol 1,3,5-orthoformate

A

D-myo-inositol
87-89-8

D-myo-inositol

B

4,6-O-methylene-myo-inositol
1259936-03-2

4,6-O-methylene-myo-inositol

Conditions
ConditionsYield
With methanol; toluene-4-sulfonic acid In chloroform at 40℃; for 48h;A n/a
B 74%
myo-inositol 1-phosphate
15421-51-9

myo-inositol 1-phosphate

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With alkaline phosphatase type III from Escherichia coli In various solvent(s) at 25℃; for 16h; pH=8.0; Substitution;63.6%
inositol peracetate
1254-38-2

inositol peracetate

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With hydrogenchloride
With sodium methylate In methanol for 2h;
benzenehexol
608-80-0

benzenehexol

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With water; hydrogen; palladium at 50 - 55℃;
With ethanol; nickel at 125℃; under 95616 Torr; Hydrogenation;
With water; palladium at 20℃; Hydrogenation.sowie bei 55grad;
sequoyitol
523-92-2

sequoyitol

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With hydrogen iodide
With hydrogen iodide Heating;0.08 g
(+)-Conduritol E epoxide
145107-29-5

(+)-Conduritol E epoxide

A

D-myo-inositol
87-89-8

D-myo-inositol

B

allo-inositol
643-10-7

allo-inositol

Conditions
ConditionsYield
With barium dihydroxide
Conditions
ConditionsYield
In water for 48h; Product distribution; biosynthesis with Simmondsia chinensis, various time;
(1R)-1-L-O-methyl-myo-inositol
22350-68-1

(1R)-1-L-O-methyl-myo-inositol

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With hydrogen iodide In water for 1h; Heating;0.1 g
With water Reflux;
D-Myo-inositol-1-monophosphate
93712-94-8

D-Myo-inositol-1-monophosphate

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
In water at 40℃; rice bran acid phosphatase, 0.2 M acetate buffer;
Myo-inositol-2-monophosphate
93712-94-8

Myo-inositol-2-monophosphate

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
In water at 40℃; rice bran acid phosphatase, 0.2 M acetate buffer;
L-Myo-inositol-3-monophosphate
93712-94-8

L-Myo-inositol-3-monophosphate

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
In water at 40℃; rice bran acid phosphatase, 0.2 M acetate buffer;
1,2:4,5-Dianhydro-cis-inosit
50474-02-7

1,2:4,5-Dianhydro-cis-inosit

A

D-myo-inositol
87-89-8

D-myo-inositol

B

muco-inositol
488-55-1

muco-inositol

Conditions
ConditionsYield
With sulfuric acid for 3h; Heating;A 14 % Spectr.
B 86 % Spectr.

A

D-myo-inositol
87-89-8

D-myo-inositol

B

muco-inositol
488-55-1

muco-inositol

C

myo-inositol
488-59-5

myo-inositol

chiro-inositol
18685-70-6

chiro-inositol

Conditions
ConditionsYield
With sulfuric acid for 3h; Heating;A 0.5 % Spectr.
B 80 % Spectr.
C 0.5 % Spectr.
D 19 % Spectr.
(1S,2R,3R,4R)-3,4-O-Isopropylidenecyclohex-5-ene-1,2,3,4-tetraol
139013-60-8

(1S,2R,3R,4R)-3,4-O-Isopropylidenecyclohex-5-ene-1,2,3,4-tetraol

A

D-myo-inositol
87-89-8

D-myo-inositol

B

muco-inositol
488-55-1

muco-inositol

Conditions
ConditionsYield
With sulfuric acid; 3-chloro-benzenecarboperoxoic acid 1.) CH2Cl2; Yield given. Multistep reaction. Yields of byproduct given;
D-myo-inositol-3-phosphate
2831-74-5

D-myo-inositol-3-phosphate

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With pAD1.88A; phosphatse from Escherichia coli JWF1
(+)-Conduritol E epoxide
145107-29-5

(+)-Conduritol E epoxide

aqueous barium hydroxide

aqueous barium hydroxide

A

D-myo-inositol
87-89-8

D-myo-inositol

B

allo-inositol
643-10-7

allo-inositol

Conditions
ConditionsYield
at 100℃;
2.3.5.6-tetrahydroxy-benzoquinone-(1.4)

2.3.5.6-tetrahydroxy-benzoquinone-(1.4)

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With water; palladium at 20℃; Hydrogenation;
With palladium on activated charcoal; water at 20℃; Hydrogenation;
levorotatory mesoinositol-tetraphosphoric acid

levorotatory mesoinositol-tetraphosphoric acid

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With water at 130℃;
With sulfuric acid at 130℃;
phytic acid

phytic acid

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With phytase
phytin

phytin

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
With mineral acid
With phytase
With water
With phytase
With sulfuric acid Hydrolysis;
myo-2-inosose
488-64-2

myo-2-inosose

water
7732-18-5

water

platinum

platinum

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
Hydrogenation;
salt of/the/ phytic acid

salt of/the/ phytic acid

D-myo-inositol
87-89-8

D-myo-inositol

tethelin

tethelin

D-myo-inositol
87-89-8

D-myo-inositol

Conditions
ConditionsYield
Hydrolysis;
D-myo-inositol
87-89-8

D-myo-inositol

phenylboronic acid
98-80-6

phenylboronic acid

rac-1:2,3:5,4:6-O1:O2,O3:O5,O4:O6-tris(phenylboronato)-myo-inositol
69814-44-4

rac-1:2,3:5,4:6-O1:O2,O3:O5,O4:O6-tris(phenylboronato)-myo-inositol

Conditions
ConditionsYield
at 95℃; for 1h;100%
D-myo-inositol
87-89-8

D-myo-inositol

cyclohexanone
108-94-1

cyclohexanone

rac-1,2-O-cyclohexylidene-myo-inositol
6763-47-9

rac-1,2-O-cyclohexylidene-myo-inositol

Conditions
ConditionsYield
Stage #1: D-myo-inositol; cyclohexanone With toluene-4-sulfonic acid In N,N-dimethyl-formamide; toluene at 122 - 136℃; for 10h; Condensation;
Stage #2: With ethanol; toluene-4-sulfonic acid at 20℃; for 48h; alcoholysis;
98%
With toluene-4-sulfonic acid97%
With toluene-4-sulfonic acid In N,N-dimethyl-formamide; toluene for 9h; Heating;93%
D-myo-inositol
87-89-8

D-myo-inositol

2,2-dimethoxy-propane
77-76-9

2,2-dimethoxy-propane

L-1,2-O-isopropylidene-myo-inositol
128387-20-2

L-1,2-O-isopropylidene-myo-inositol

Conditions
ConditionsYield
With toluene-4-sulfonic acid In dimethyl sulfoxide98%
D-myo-inositol
87-89-8

D-myo-inositol

acetic anhydride
108-24-7

acetic anhydride

inositol peracetate
1254-38-2

inositol peracetate

Conditions
ConditionsYield
With copper(II) perchlorate hexahydrate In neat (no solvent) at 20℃; for 0.166667h; Inert atmosphere;95%
iron(III) chloride at 28 - 32℃; for 0.166667h;86%
With zinc(II) chloride
D-myo-inositol
87-89-8

D-myo-inositol

n-decanoyl chloride
112-13-0

n-decanoyl chloride

Hexa-O-decanoyl-myo-inosit

Hexa-O-decanoyl-myo-inosit

Conditions
ConditionsYield
With trifluoroacetic acid for 15h; Ambient temperature;95%
D-myo-inositol
87-89-8

D-myo-inositol

benzoyl chloride
98-88-4

benzoyl chloride

Triethyl orthoacetate
78-39-7

Triethyl orthoacetate

2,4,6-tri-O-benzoyl-myo-inosityl 1,3,5-orthoacetate

2,4,6-tri-O-benzoyl-myo-inosityl 1,3,5-orthoacetate

Conditions
ConditionsYield
Stage #1: D-myo-inositol; Triethyl orthoacetate With toluene-4-sulfonic acid In N,N-dimethyl-formamide for 8h; Heating;
Stage #2: benzoyl chloride In pyridine at 20℃;
95%
D-myo-inositol
87-89-8

D-myo-inositol

benzoyl chloride
98-88-4

benzoyl chloride

1,3-di-O-benzoyl-myo-inositol
162062-52-4

1,3-di-O-benzoyl-myo-inositol

Conditions
ConditionsYield
With triethylamine; lithium chloride In N,N-dimethyl acetamide at -10℃; for 4h; regioselective reaction;95%
Stage #1: D-myo-inositol; benzoyl chloride With triethylamine; lithium chloride In N,N-dimethyl acetamide at -10℃; for 4h;
Stage #2: With pyridine; chloro-trimethyl-silane In N,N-dimethyl acetamide at 0℃; for 5h;
Stage #3: With trifluoroacetic acid In methanol; chloroform at 20℃; for 4h;
95%
D-myo-inositol
87-89-8

D-myo-inositol

propionic acid anhydride
123-62-6

propionic acid anhydride

Hexakispropionylmyoinositol
5776-50-1

Hexakispropionylmyoinositol

Conditions
ConditionsYield
With Cl(1-)*C5H14NO(1+)*3ZnCl2 In neat (no solvent) at 20℃; for 2h; Green chemistry;95%
Trimethyl orthoacetate
1445-45-0

Trimethyl orthoacetate

D-myo-inositol
87-89-8

D-myo-inositol

allyl bromide
106-95-6

allyl bromide

C18H30O9

C18H30O9

Conditions
ConditionsYield
Stage #1: Trimethyl orthoacetate; D-myo-inositol With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 100℃; for 2h;
Stage #2: allyl bromide With sodium hydride In N,N-dimethyl-formamide at 20℃; for 3h; Further stages;
95%
D-myo-inositol
87-89-8

D-myo-inositol

benzoyl chloride
98-88-4

benzoyl chloride

orthoformic acid triethyl ester
122-51-0

orthoformic acid triethyl ester

(1R,3s,5r,6R,7S,8s,9S)-2,4,10-trioxaadamantane-6,8,9-triyl tribenzoate

(1R,3s,5r,6R,7S,8s,9S)-2,4,10-trioxaadamantane-6,8,9-triyl tribenzoate

Conditions
ConditionsYield
Stage #1: D-myo-inositol; orthoformic acid triethyl ester With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 100℃;
Stage #2: benzoyl chloride In pyridine at 20℃;
94%
D-myo-inositol
87-89-8

D-myo-inositol

orthobenzoic acid trimethyl ester
707-07-3

orthobenzoic acid trimethyl ester

C13H14O6

C13H14O6

Conditions
ConditionsYield
With camphor-10-sulfonic acid In dimethyl sulfoxide Inert atmosphere;94%
With toluene-4-sulfonic acid In dimethyl sulfoxide at 100℃; for 5h; Inert atmosphere;
D-myo-inositol
87-89-8

D-myo-inositol

dimethyl sulfoxide
67-68-5

dimethyl sulfoxide

C11H16O8

C11H16O8

Conditions
ConditionsYield
With trichlorophosphate at 65℃; for 0.5h;92%
D-myo-inositol
87-89-8

D-myo-inositol

1,1,1-Trimethoxy-2,2-dimethyl-propane
97419-16-4

1,1,1-Trimethoxy-2,2-dimethyl-propane

3-tert-Butyl-2,4,10-trioxa-tricyclo[3.3.1.13,7]decane-6,8,9-triol

3-tert-Butyl-2,4,10-trioxa-tricyclo[3.3.1.13,7]decane-6,8,9-triol

Conditions
ConditionsYield
With camphor-10-sulfonic acid In dimethyl sulfoxide at 60℃; for 15h;91%
D-myo-inositol
87-89-8

D-myo-inositol

trimethyl orthoformate
149-73-5

trimethyl orthoformate

myo-inosytol 1,3,5-orthoformate

myo-inosytol 1,3,5-orthoformate

Conditions
ConditionsYield
With toluene-4-sulfonic acid In N,N-dimethyl-formamide Inert atmosphere;91%
toluene-4-sulfonic acid In DMF (N,N-dimethyl-formamide) at 120℃; for 7h;
Trimethyl orthoacetate
1445-45-0

Trimethyl orthoacetate

D-myo-inositol
87-89-8

D-myo-inositol

myo-inositol 1,3,5-orthoacetate

myo-inositol 1,3,5-orthoacetate

Conditions
ConditionsYield
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 90 - 100℃;91%
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 100℃; for 10h;10%
D-myo-inositol
87-89-8

D-myo-inositol

orthoformic acid triethyl ester
122-51-0

orthoformic acid triethyl ester

myo-Inositol orthoformate
98510-20-4

myo-Inositol orthoformate

Conditions
ConditionsYield
With Amberlyst 15 In N,N-dimethyl-formamide at 100℃; for 3h;90%
With toluene-4-sulfonic acid In N,N-dimethyl-formamide89%
With o-toluenesulfonic acid In N,N-dimethyl-formamide at 100℃; for 16h;84%
D-myo-inositol
87-89-8

D-myo-inositol

isobutyryl chloride
79-30-1

isobutyryl chloride

Hexakisisobutyrylmyoinositol
32077-77-3

Hexakisisobutyrylmyoinositol

Conditions
ConditionsYield
With pyridine; dmap at 80 - 85℃; for 1h;90%
D-myo-inositol
87-89-8

D-myo-inositol

orthobenzoic acid trimethyl ester
707-07-3

orthobenzoic acid trimethyl ester

myo-inositol 1,3,5-orthobenzoate

myo-inositol 1,3,5-orthobenzoate

Conditions
ConditionsYield
With camphor-10-sulfonic acid In dimethyl sulfoxide at 80℃; under 22.5023 - 30.003 Torr; for 3h;90%
With camphor-10-sulfonic acid In dimethyl sulfoxide at 80℃; for 5h;84%
With H2SO4 supported on silica In dimethyl sulfoxide at 60℃; under 300.03 Torr; for 0.5h; Inert atmosphere; Green chemistry;83%
D-myo-inositol
87-89-8

D-myo-inositol

acetic anhydride
108-24-7

acetic anhydride

1,3-di-O-acetyl-myo-inositol
1431370-12-5

1,3-di-O-acetyl-myo-inositol

Conditions
ConditionsYield
With dibutyltin diacetate; triethylamine; lithium chloride In N,N-dimethyl acetamide at -10℃; for 2h;90%
isocyanate de chlorosulfonyle
1189-71-5

isocyanate de chlorosulfonyle

D-myo-inositol
87-89-8

D-myo-inositol

myo-inositol hexacarbamate

myo-inositol hexacarbamate

Conditions
ConditionsYield
In acetonitrile at 20℃; for 1.5h; Cooling with ice;90%
D-myo-inositol
87-89-8

D-myo-inositol

orthoformic acid triethyl ester
122-51-0

orthoformic acid triethyl ester

myo-inositol-1,3,5-O-orthoformate

myo-inositol-1,3,5-O-orthoformate

Conditions
ConditionsYield
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 100℃; for 24h;89%
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 140℃; for 3h;87%
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 110℃; for 28h; Inert atmosphere;83%
D-myo-inositol
87-89-8

D-myo-inositol

trimethyl orthoformate
149-73-5

trimethyl orthoformate

myo-Inositol orthoformate
98510-20-4

myo-Inositol orthoformate

Conditions
ConditionsYield
With TSA In N,N-dimethyl-formamide at 110℃; for 5h;89%
In N,N-dimethyl-formamide70%
With toluene-4-sulfonic acid In N,N-dimethyl-formamide at 99.9℃; for 3h;
D-myo-inositol
87-89-8

D-myo-inositol

tert-butylchlorodiphenylsilane
58479-61-1

tert-butylchlorodiphenylsilane

1,3-di-O-tert-butyldiphenylsilyl-myo-inositol
1196789-46-4

1,3-di-O-tert-butyldiphenylsilyl-myo-inositol

Conditions
ConditionsYield
With pyridine In dimethyl sulfoxide at 20℃; for 72h; regioselective reaction;89%
With pyridine In dimethyl sulfoxide at 20℃; for 72h;89%
D-myo-inositol
87-89-8

D-myo-inositol

1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane
69304-37-6

1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane

1,6:3,4-bis-O-(tetraisopropyldisiloxane-1,3-diyl)-myo-inositol
123270-13-3

1,6:3,4-bis-O-(tetraisopropyldisiloxane-1,3-diyl)-myo-inositol

Conditions
ConditionsYield
With pyridine In dimethyl sulfoxide at 20℃; for 20h; regioselective reaction;88%
With pyridine In dimethyl sulfoxide at 20℃; for 20h;88%
With pyridine Ambient temperature;66%
D-myo-inositol
87-89-8

D-myo-inositol

pivaloyl chloride
3282-30-2

pivaloyl chloride

1,3-di-O-pivaloyl-myo-inositol
1196789-44-2

1,3-di-O-pivaloyl-myo-inositol

Conditions
ConditionsYield
With triethylamine; lithium chloride In N,N-dimethyl acetamide at 0℃; for 10h; regioselective reaction;88%
With triethylamine; lithium chloride In N,N-dimethyl acetamide at 0℃; for 10h;88%

87-89-8Relevant academic research and scientific papers

Forced degradation of L-(+)-bornesitol, a bioactive marker of Hancornia speciosa: Development and validation of stability indicating UHPLC-MS method and effect of degraded products on ACE inhibition

Gomes, José Hugo de Sousa,da Silva, Grazielle Caroline,C?rtes, Steyner F.,de Pádua, Rodrigo Maia,Braga, Fern?o Castro

, p. 31 - 38 (2018)

The antihypertensive activity of the medicinal plant Hancornia speciosa has been previously demonstrated by us, being the activity ascribed to polyphenols and cyclitols like L-(+)-bornesitol. We herein evaluated the stability of the bioactive marker bornesitol submitted to forced degradation conditions. Bornesitol employed in the study was isolated from H. speciosa leaves. An UHPLC-ESI-MS/MS method was developed to investigate bornesitol stability based on MRM (Multiple Reaction Monitoring) acquisition mode and negative ionization mode, employing both specific (m/z 193 → 161 Da) and confirmatory (m/z 193 → 175 Da) transitions. A gradient elution of 0.1% formic acid in water and acetonitrile was performed on a HILIC column. The method was validated and showed adequate linearity (r2 > 0.99), selectivity, specificity, accuracy, and precision (RSD 2.9%). The method was robust for deliberate variations on dessolvation temperature, but not for changes in the flow rate and dessolvation gas. The results from the stability studies allowed us to classify bornesitol as labile for acidic and alkaline hydrolysis, but as very stable for oxidative and neutral hydrolysis exposure. Bornesitol was categorized as practically stable under photolysis degradation, whereas a considerable reduction on its contents was induced by metal ions and thermolysis exposure. Degraded samples from neutral hydrolysis and thermolysis were assayed in vitro for ACE inhibition and showed a substantial decrease in biological activity as compared to intact bornesitol. myo-Inositol was identified as the major degradation products in both matrices. This is the first report on bornesitol stability under different stress conditions and the obtained data are relevant for the development and quality control of standardized products from H. speciosa leaves.

Analysis of metabolically labeled inositol phosphate messengers by NMR

Puschmann, Robert,Harmel, Robert K.,Fiedler, Dorothea

, p. 35 - 52 (2020/06/23)

Inositol phosphates (InsPs) are an important group of eukaryotic messengers and mediate a wide range of processes. To elucidate the biological functions of these molecules, robust techniques to characterize inositol phosphate metabolism at the cellular level are highly sought after. This chapter provides a detailed protocol for the preparation of 13C-labeled myo-inositol, its use for metabolic labeling of mammalian and yeast cells, and the quantitative analysis of intracellular InsP pools from cell extracts using NMR spectroscopy.

METHODS OF EXTRACTING PHOSPHORUS FROM DISTILLATES

-

Paragraph 0029; 0099, (2016/11/28)

Methods of processing distillates, methods of removing at least some portion of total phosphorus in a distillate, methods of removing at least some portion of the soluble inorganic phosphorus, phytate phosphorus, or some combination thereof in a distillate, methods for obtaining phytate from distillates, methods for producing phytate derivatives and combinations thereof.

Method for the production of inositol phytin

-

Paragraph 0021-0024, (2017/03/17)

The invention discloses a method for preparing inositol by adopting phytine. The method comprises the following steps: with the phytine as a raw material, adding deionized water and the phytine into a reactor according to a weight ratio of (5-20):1 of liquid to material, regulating the pH value to 4-5.5, adding phytase of which the weight is 0.5-3 percent of that of the phytine, stirring for hydrolysis under the assistance of ultrasonic waves, and controlling the temperature of a reaction system to be 37-50 DEG C, wherein the action time of the ultrasonic waves is 0.5-1 hour in the hydrolysis process, and the start time of the action of the ultrasonic waves is 0-50 percent of the total reaction time; ending the hydrolysis reaction after the hydrolysis is performed for 4-24 hours, adding solid super-acid of which the weight is 0.2-1 percent of that of the phytine into hydrolysate, performing complete hydrolysis for 15-45 minutes under a pressure of 0.12-0.20 MPa at the reaction temperature of 105-120 DEG C, filtering, adding filtrate into a water solution of calcium oxide, regulating the pH to 7.0, filtering, concentrating the filtrate until the ratio of the liquid to the material is 2:1 based on the initial weight of the phytine, then adding ethanol in a plurality of steps and respectively separating and precipitating to finally obtain the inositol. The method disclosed by the invention has the advantages of low pressure, low temperature and low energy consumption.

Elaboration of the ether cleaving ability and selectivity of the classical Pearlman's catalyst [Pd(OH)2/C]: Concise synthesis of a precursor for a myo-inositol pyrophosphate

Mart, Alson,Shashidhar, Mysore S.

, p. 9769 - 9776,8 (2012/12/11)

The cleavage of propargyl, allyl, benzyl, and PMB ethers by Pd(OH) 2/C can be tuned in that order, by varying the reaction conditions. Other moieties such as C-C double bonds, esters, trityl ether, p-bromo and p-nitrobenzyl ethers are stable to these reaction conditions. Cleavage of allyl ethers can be made catalytic by using 1:1 mixture of Pd(OH)2/C and Pd/C. The synthetic potential of the selective ether cleaving ability of Pd(OH)2/C, essentially under neutral conditions, has been demonstrated by an efficient synthesis of a precursor for the preparation of an inositol pyrophosphate derivative.

Elaboration of the ether cleaving ability and selectivity of the classical Pearlman's catalyst [Pd(OH)2/C]: Concise synthesis of a precursor for a myo-inositol pyrophosphate

Mart, Alson,Shashidhar, Mysore S.

, p. 9769 - 9776 (2013/01/13)

The cleavage of propargyl, allyl, benzyl, and PMB ethers by Pd(OH) 2/C can be tuned in that order, by varying the reaction conditions. Other moieties such as C-C double bonds, esters, trityl ether, p-bromo and p-nitrobenzyl ethers are stable to these reaction conditions. Cleavage of allyl ethers can be made catalytic by using 1:1 mixture of Pd(OH)2/C and Pd/C. The synthetic potential of the selective ether cleaving ability of Pd(OH)2/C, essentially under neutral conditions, has been demonstrated by an efficient synthesis of a precursor for the preparation of an inositol pyrophosphate derivative.

Protecting group directed stereoselective reduction of an epi-inosose: Efficient synthesis of epi-inositol

Patil, Madhuri T.,Krishnaswamy, Shobhana,Sarmah, Manash P.,Shashidhar, Mysore S.

supporting information; experimental part, p. 3756 - 3758 (2011/08/06)

A facile and high yielding synthesis of epi-inositol via stereoselective reduction of a pentaprotected epi-inosose is reported. Extent of stereoselectivity during the hydride reduction appears to depend on the ability of the substrate to complex with metal ions in the reducing agent.

In vitro and in vivo antioxidant activity of a water-soluble polysaccharide from dendrobium denneanum

Luo, Aoxue,Ge, Zhongfu,Fan, Yijun,Luo, Aoshuang,Chun, Ze,Jin He, Xing

experimental part, p. 1579 - 1592 (2011/04/25)

The water-soluble crude polysaccharide (DDP) obtained from the aqueous extracts of the stem of Dendrobium denneanum through hot water extraction followed by ethanol precipitation, was found to have an average molecular weight (Mw) of about 484.7 kDa. Monosaccharide analysis revealed that DDP was composed of arabinose, xylose, mannose, glucose and galactose in a molar ratio of 1.00:2.66:8.92:34.20:10.16. The investigation of antioxidant activity both in vitro and in vivo showed that DDP is a potential antioxidant.

Conformational study of the natural iron chelator myo-inositol 1,2,3-trisphosphate using restrained/flexible analogues and computational analysis

Mansell, David,Veiga, Nicolás,Torres, Julia,Etchells, Laura L.,Bryce, Richard A.,Kremer, Carlos,Freeman, Sally

experimental part, p. 8949 - 8957 (2011/01/04)

Myo-Inositol 1,2,3-trisphosphate [Ins(1,2,3)P3], a component in mammalian cells, possesses the correct chemical properties of an intracellular iron transit ligand. Here we have examined the conformation of the Ins(1,2,3)P3-Fe3+ complex. The synthesis and antioxidant properties of 4,6-carbonate-myo-inositol 1,2,3,5-tetrakisphosphate [4,6-carbonate Ins(1,2,3,5)P4], which is locked in the unstable penta-axial chair conformation and 1,2,3-trisphosphoglycerol, a flexible acyclic analogue of Ins(1,2,3)P3, are reported. 4,6-Carbonate Ins(1,2,3,5)P4 caused complete inhibition of iron-catalysed hydroxyl radical (HO?) formation at 100 μM, thereby resembling Ins(1,2,3)P3 and supporting a penta-axial chair binding conformation. In contrast, 1,2,3-trisphosphoglycerol was shown to have incomplete antioxidant properties. In support of experimental observations, we have applied high-level density functional calculations to the binding of Ins(1,2,3)P3 to iron. This study provides evidence that Fe3+ binds tightly to the less stable penta-axial conformation of Ins(1,2,3)P3 using terminal and bridging phosphate oxygens, thought to also contain a tightly bound water molecule or hydroxyl ligand in the complex.

BIOOCOMPATIBLE POLYMER COMPOSITIONS

-

, (2010/01/31)

The present invention provides a biocompatible prepolymer comprising hydrophilic and hydrophobic segments, wherein the hydrophobic segments have at least one ethylenically unsaturated functional group and at least 5% of the segments have two or more ethylenically unsaturated functional groups and water. The invention further provides a biocompatible prepolymer composition comprising hydrophilic and hydrophobic prepolymers, wherein at least one of the hydrophobic prepolymers has at least one ethylenically unsaturated functional group and at least 5% of the prepolymers have two or more ethylenically unsaturated functional groups and water. The invention further provides use of the prepolymer or prepolymer compositions of the invention in biomedical applications such as tissue engineering, as bone substitutes or scaffolds, and in wound treatment.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 87-89-8